Surmodics Inc (SRDX): Bryan K Phillips , SVP, Gen Counsel & Secretary of Surmodics Inc sold 1,816 shares on Jun 14, 2016. The Insider selling transaction was reported by the company on Jun 16, 2016 to the Securities and Exchange Commission. The shares were sold at $23.44 per share for a total value of $42,560.87 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 14, 2016, Joseph J. Stich (VP, Bus Ops & GM, IVD) sold 1,000 shares at $23.33 per share price.On Jun 2, 2016, Susan E Knight (director) sold 2,330 shares at $22.35 per share price.Also, On Mar 7, 2016, Timothy J. Arens (VP-Corporate Dev. and Strategy) sold 10,291 shares at $18.42 per share price.On Aug 7, 2015, Charles W Olson (Senior VP & GM, Med Dev) sold 10,000 shares at $26.16 per share price.
SurModics: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in SurModics which led to swings in the share price. The shares opened for trading at $23.78 and hit $24.03 on the upside , eventually ending the session at $23.84, with a gain of 0.63% or 0.15 points. The heightened volatility saw the trading volume jump to 69,223 shares. The 52-week high of the share price is $27.68 and the company has a market cap of $310 M . The 52-week low of the share price is at $17.45.
Company has been under the radar of several Street Analysts.SurModics is Reiterated by Barrington Research to Outperform and the brokerage firm has raised the Price Target to $ 30 from a previous price target of $27 .The Rating was issued on May 3, 2016.
SurModics Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates in two reportable segments: the Medical Device unit which is comprised of surface modification coating technologies to improve access deliverability and predictable deployment of medical devices as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device with end markets that include coronary peripheral and neurovascular and urology among others and the In Vitro Diagnostics unit which consists of component products and technologies for diagnostic immunoassay and molecular tests and biomedical research applications with products that include protein stabilization reagents substrates antigens and surface coatings.